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Evidence for colorectal cancer cell specificity of aspirin effects on
NFkB signalling and apoptosis
FVN Din1, MG Dunlop*,1 and LA Stark1
1Colon Cancer Genetics Group, University of Edinburgh Department of Oncology and MRC Human Genetics Unit, Western General Hospital, Crewe Rd,
Edinburgh EH4 2XU, Scotland
Epidemiological evidence indicates that non-steroidal anti-inflammatory drugs (NSAIDs) protect against colorectal cancer (CRC) to a
greater degree than other non-gastrointestinal cancers, but the molecular basis for this difference is unknown. We previously reported
that aspirin induces signal-specific IkBa degradation followed by NFkB nuclear translocation in CRC cells, and that this mechanism
contributes substantially to aspirin-induced apoptosis. Here, we explored the hypothesis that cell-type specific effects on NFkB
signalling are responsible for the observed differences in protection by aspirin against CRC compared to breast and gynaecological
cancers. We also assessed whether COX-2 expression, mutation status of adenomatous polyposis coli (APC), b-catenin, p53, or DNA
mismatch repair (MMR) genes in CRC lines influenced aspirin-induced effects. We found that aspirin induced concentration-dependent
IkBa degradation, NFkB nuclear translocation and apoptosis in all CRC lines studied. However, there was no such effect on the other
cancer cell types, indicating a considerable degree of cell-type specificity. The lack of effect on NFkB signalling, paralleled by absence of
an apoptotic response to aspirin in non-CRC lines, strongly suggests a molecular rationale for the particular protective effect of NSAIDs
against CRC. Effects on NFkB and apoptosis were observed irrespective of COX-2 expression, or mutation status in APC, b-catenin,
p53 and DNA MMR genes, underscoring the generality of the aspirin effect on NFkB in CRC cells. These findings raise the possibility of
cell-type specific targets for the development of novel chemopreventative agents.
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Colorectal cancer (CRC) is common in developed countries
(Parkin et al, 1999) and is a major contributor to cancer-related
morbidity and mortality. Chemoprevention is an inherently
appealing approach to combat the disease, and non-steroidal
anti-inflammatory drugs (NSAIDs) have been associated with a
substantial reduction in CRC incidence and mortality (Thun et al,
1993; Collet et al, 1999; Langman et al, 2000). Combined case–
control data, including over 30 000 CRC cases, indicate a 45%
reduction in the risk of developing CRC in subjects taking NSAIDs.
Although there is evidence for a protective effect of NSAIDs
against non-gastrointestinal cancers, the data are less convincing
and the risk reduction much less. In breast cancer, reports show
conflicting results and a recent meta-analysis revealed a risk
reduction of only 13% in case– control studies (Khuder and Mutgi,
2001), considerably lesser than that in CRC. Similarly, in
endometrial and ovarian cancer, the available evidence suggests
that NSAIDs confer little, if any, protection (Cramer et al, 1998;
Rosenberg et al, 2000; Fairfield et al, 2002; Meier et al, 2002).
Collectively, published data suggest that there is considerable
heterogeneity of NSAID anti-tumour effect between cancer types.
The particular protective effect against CRC suggests the
possibility that aspirin might target distinct molecular pathways
in colonic epithelial cells. Elucidation of the molecular mechanism
of this apparent differential sensitivity would lend further insight
into both the mode of action of NSAIDs as well as identification of
molecular markers of response.
The anti-tumour activity of NSAIDs has primarily been
attributed to inhibition of the cyclooxygenase-2 enzyme (COX-2)
and the resultant decrease in production of prostaglandins, as this
remains the best-characterised effect (Vane, 1971). However,
accumulating evidence from animal and cell culture experiments
has shown that COX-2 inhibition is not the sole basis of NSAID
anti-tumour activity (Alberts et al, 1995; Hanif et al, 1996; Elder
et al, 1997; Piazza et al, 1997), suggesting that other targets are also
involved. We previously reported that aspirin activates the NFkB
signalling pathway and that this mechanism is of central
importance to aspirin-mediated apoptosis in CRC cells (Stark
et al, 2001). The NFkB transcription factor is normally sequestered
in the cytoplasm by an inhibitor protein, IkBa. Following
stimulation of the NFkB pathway, IkBa is phosphorylated,
ubiquitinated and targeted for proteosomal degradation. Dissocia-
tion from IkBa results in translocation of NFkB to the nucleus,
where it contributes to the co-ordinated transcription of genes
involved in inflammation, cell proliferation and apoptosis (Pahl,
1999). Our previous work demonstrated that aspirin induces time-
and dose-dependent signal-specific degradation of IkBa, nuclear
translocation of NFkB and apoptosis in CRC cells. Time-course
experiments indicated that IkBa degradation and NFkB nuclear
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translocation preceded cell death, suggesting a causal relationship.
This was confirmed in cells we engineered to continuously express
a dominant-negative mutant IkBa (IkBaS32/36), which showed
inhibition of both aspirin-induced NFkB nuclear translocation and
apoptosis compared to their parental counterparts (Stark et al,
2001). This work alluded to the notion of specificity since the
NFkB response was not observed in the control cell lines 293 HEK
and A549, which were non-colorectal in origin.
Here, we focus on the important issue of the specificity of
aspirin’s protective effects, as observed in epidemiological studies,
and we set out to determine whether cell-type specific effects on
the NFkB signalling pathway reflect the differential protective
effects of aspirin in different cancer types. In particular, we wished
to determine whether the lower protective effect observed for
breast, ovarian and endometrial cancer can be explained by
differing effects on the NFkB signalling pathway. We also
investigated the generality of the NFkB response to aspirin in
CRC by studying a panel of CRC cell lines with different genetic
defects common in bowel malignancy. Here, we present evidence
showing clear differences in NFkB response that parallel the
epidemiological data, supporting the notion that the ability of
aspirin to modulate the NFkB signalling pathway is a key
determinant of the anti-tumour effect and that this is cell-type
specific. Our findings provide further insight into the complex
mechanisms by which NSAIDs exert an anti-tumour effect in CRC
cells, and raise the possibility of cell-type specific molecular targets
in CRC.
MATERIALS AND METHODS
Cell line culture and treatment
The CRC cell lines used were HRT-18, SW480, HT-29, DLD-1,
LoVo and HCT116; breast cancer lines were T47-D, MCF-7 and
MDA-MB-231; ovarian cancer line was A2780 and endometrial
cancer line was HEC-1-A. All cancer cell lines are available from
the American Type Culture Collection. The mutation status for the
adenomatous polyposis coli (APC), p53, b-catenin and DNA
mismatch repair (MMR) genes of the cell lines studied is shown in
Table 1. Cell lines were grown as monolayers (371C in 5% CO2) in
RPMI (HRT-18, DLD-1 and A2780), DMEM (HT-29, T47-D, MCF-
7, MDA-MB-231, HEC-1-A), L-15 (SW480) and McCoy’s 5A media
(HCT116) supplemented with 10% foetal calf serum (FCS) and 1%
penicillin/streptomycin (media supplied by Gibco BRL, Paisley,
UK). Cells were plated (1 106 cells/50 ml flask) and grown until
60–70% confluent, prior to treatment with aspirin or carrier
control at the same concentrations as the aspirin treatment.
Aspirin (Sigma, St Louis, USA) was prepared as a 0.5 M stock
solution in distilled water (final pH 7.0). Growth medium was
replaced with the respective low serum (0.5% FCS) medium and
cells were treated with aspirin at 1, 3, 5 and 10 mM for 24 h (or
72 h), or with carrier as a control.
Cell viability and determination of apoptosis
Adherent cells were harvested and viable cell number determined
by haemocytometric counts with nigrosin exclusion. IC50 values
for the CRC cell lines were calculated using the XLfit 3t software.
Apoptosis was detected via its interaction with annexin V using an
Annexin V-FITC apoptosis detection kit (Oncogene Research
Products, Cambridge, MA, USA), as per the manufacturer’s
instructions. Briefly, the medium from the flask of adherent cells
was transferred to a conical tube on ice to harvest any floating
cells. Cells were then washed with 2 ml of PBS, which was also
added to the tube to collect any cells dislodged during washing.
Cells were incubated with 1 ml of trypsin : versene (volume per
volume) just until the cells detached and then resuspended in the
conical tube containing the media with the floating and washed
cells. Cells were counted using a haemocytometer and resuspended
in cold 1 binding buffer to approximately 1 106 cells ml1.
Media-binding reagent (10ml) was added to 0.5 ml of the cell
suspension, which was incubated with 1.25 ml of annexin V-FITC
for 15 min at room temperature in the dark. Annexin V was then
removed by centrifugation at 1000 g for 5 min and the cells were
resuspended in 0.5 ml of cold 1 binding buffer and placed on ice.
The counting was done using a haemocytometer (two counting
grids) in duplicate and this was carried out immediately following
staining of cells, as apoptosis is an ongoing process and the FITC
signal may be lost after an hour.
Western blotting
Cells were washed with PBS, centrifuged (1200 r.p.m., 10 min) and
cell pellets resuspended in lysis buffer (50 mM NaCl, 10 mM HEPES,
500 mM sucrose, 1 mM EDTA, 0.5 mM spermidine, 0.15 mM sper-
mine, 0.2% Triton X-100) containing complete Protease Inhibitor
Cocktail and 100 mM Pefabloc (Roche Diagnostics, Manheim,
Germany). The cell suspension was centrifuged (6000 r.p.m.,
15 min, 41C) and the supernatant containing cytoplasmic proteins
aliquoted. Protein content was measured by the method of
Bradford (BioRad, Hercules, California, USA). Cytoplasmic
proteins (30 mg) were separated on a 10% SDS– PAGE gel,
transferred to a polyvinylidine difluoride membrane (BioRad)
and blocked in 4% non-fat dry milk solution with 0.3% Tween20
(Sigma). Membranes were probed with a sheep polyclonal IkBa
antibody (a gift from Professor R Hay, University of St Andrews,
UK), rabbit polyclonal p65 antibody (Santa Cruz, California, USA)
or mouse monoclonal COX-2 antibody (Cayman Chemicals,
Michigan, USA). COX-2 electrophoresis standard (Cayman Che-
micals) was used to indicate the correct COX-2 band. Monoclonal
antibody to Cu/Zn SOD (The Binding Site, Birmingham, UK) and
to actin (Santa Cruz) was used as a control for protein loading.
Antigen–antibody complexes were visualised with chemilumines-
cence (Amersham ECL Reagents, UK).
Immunofluorescence analysis
Cells grown to 60–70% confluence on glass coverslips were treated
with carrier or 10 mM aspirin for 24 h (in the respective 0.5% FCS
medium). After treatment, cells were washed with PBS, fixed with
acetone : methanol (volume per volume) (201C, 10 min) and
blocked in 10% pre-immune donkey serum (Sigma) for 1 h. Rabbit
polyclonal antibody to NFkB p65 (Santa Cruz) was applied for 1 h,
followed by incubation with FITC-conjugated donkey anti-rabbit
IgG for 1 h. The nuclei were stained with DAPI and the coverslips
mounted with Vectashield (Vector Laboratories, Burlingame,
California, USA).
Table 1 Mutation status of cancer cell lines studied
Cell line APC b-catenin p53 MMR
HRT-18 Mutant Wild type Mutant Deficient
SW480 Mutant Wild type Mutant Proficient
HT-29 Mutant Wild type Mutant Proficient
DLD-1 Mutant Wild type Mutant Deficient
LoVo Mutant Wild type Wild type Deficient
HCT-116 Wild type Mutant Wild type Deficient
MCF-7 Wild type Wild type Wild type Proficient
MDA-MB231 Wild type Wild type Mutant Not known
T47D Wild type Wild type Mutant Proficient
A2780 Wild type Wild type Wild type Proficient
HEC-1-A Not known Not known Not known Deficient
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RESULTS
Colorectal cancer cells are more susceptible to aspirin-
induced apoptosis than non-CRC cells
We studied the effect of aspirin on the growth of a panel of CRC
cell lines (HRT-18, SW480, HT-29, DLD-1, LoVo and HCT116) in
comparison to cell lines derived from other cancer types: breast
(MCF-7, MDA-MB-231, T47D), ovarian (A2780) and endometrial
(HEC-1-A). The non-CRC cell lines were chosen based on
epidemiological data, where there is some evidence to suggest a
protective effect in breast cancer and less so in ovarian and
endometrial cancer.
In triplicate dose –response experiments, cell lines were treated
for 24 h with aspirin at concentrations of 1, 3, 5 and 10 mM, and
viable cell number determined by haemocytometric counts. We
found a concentration-dependent decrease in viable cell number in
each of the six CRC cell lines studied (Figure 1A). In contrast, there
was no demonstrable effect of aspirin on the viability of the non-
CRC cell lines MCF-7, MDA-MB-231, A2780 and HEC-1-A
(Figure 1A). Interestingly, the T47D breast cancer cells did exhibit
a dose-dependent reduction in viability, although this effect was
not so pronounced as that seen in CRC cells at low aspirin
concentrations. The IC50 values were calculated from the growth
curves of the aspirin-treated CRC cell lines only, as there was no
consistent reduction in cell viability in the non-CRC cell lines
(Table 2). The mean IC50 value for the CRC cell lines was 2.38 mM
and the greatest incremental reduction in viability in these cells
was observed between 0 and 1 mM concentrations, which is
comparable to serum concentrations attainable in humans (Pach-
man et al, 1979).
We next wished to establish whether the reduction in viable cell
number that we observed in the CRC cell lines was due to
induction of apoptosis. Annexin-V binding of phosphatidylserine
residues externalised during apoptosis was used to determine the
proportion of cells undergoing programmed cell death in response
to increasing concentrations of aspirin. We found that aspirin
treatment induced a concentration-dependent increase in apopto-
sis in all six of the CRC cell lines studied, confirming that
induction of apoptosis is responsible for the observed reduction in
cell viability (Figure 1B). There was no dose-dependent increase in
apoptosis in the non-CRC cell lines following aspirin treatment,
which was consistent with the lack of effect on cell viability
(Figure 1A). Although the T47D breast cancer cells did exhibit a
reduction in viable cell count, this effect was less marked than that
seen in CRC cells and, furthermore, there was no increase in
apoptosis in this cell line. To confirm that the non-CRC cells were
less sensitive to apoptosis, we treated three non-CRC cell lines (two
breast and one ovarian) and one CRC cell line (SW480) with
aspirin for a longer time period of 72 h. Indeed, the non-CRC cell
lines were far less susceptible to apoptosis compared to the CRC
cell line despite treatment with aspirin for 72 h (Figure 1C). These
findings demonstrate that the anti-tumour activity of aspirin has a
substantial degree of specificity for CRC cells in vitro, reflecting the
epidemiological evidence for a greater protective effect against
CRC compared to other cancer types.
We also considered whether defects in genes commonly mutated
in CRC, and known to affect apoptotic pathways, might influence
such cell death. Mutation status for APC, b-catenin, p53 and DNA
MMR genes (Table 1) does not appear to influence aspirin-induced
apoptosis in CRC lines, emphasising the relevance of the aspirin
NFkB anti-tumour effect to CRC in general.
Differential sensitivity to the apoptotic effects of aspirin is
paralleled by differing responses of the NFjB pathway
Our previous work indicates that NFkB nuclear translocation is a
key component of aspirin-induced apoptosis in CRC cells. We
therefore considered whether the variations in cell viability,
observed between CRC and non-CRC cell lines, were attributable
to differing responses of the NFkB pathway to aspirin. We first
investigated the effect of aspirin on cytoplasmic levels of the NFkB
inhibitor protein IkBa, using immunoblot analysis. We found that
aspirin treatment resulted in concentration-dependent degrada-
tion of IkBa, as indicated by a reduction in cytoplasmic IkBa
protein levels (Figure 2A) in all CRC cell lines. Although the IkBa
degradation may be more obvious at the higher doses, there is
degradation at the lower doses of 1 and 3 mM aspirin (Figure 2A).
The IC50 values for the CRC cell lines range from 1.48 to 3.12 mM
aspirin, demonstrating differential sensitivity to aspirin with
respect to the concentration at which 50% of the cells are growth
inhibited (Table 2). The SW480 and HT-29 cell lines have IC50
values at the lower end of the range (1.48 and 1.98 mM,
respectively) and do undergo IkBa degradation at 1 mM, whereas
the HRT-18 and DLD-1 cell lines have IC50 values of 3.12 and
2.92 mM and also exhibit IkBa degradation at 3 mM. Hence, there is
a close relationship between IC50 values and IkBa degradation for
the individual CRC cell lines. In striking contrast, there was no
change in IkBa levels upon aspirin treatment in any of the non-
CRC cell lines even at the highest dose of 10 mM (Figure 2B).
Since these findings suggested a cell-type specific NFkB
response to aspirin, we next determined whether the disparate
IkBa response was accompanied by a differential effect on NFkB
nuclear translocation in the CRC compared to the non-CRC cell
lines. Immunofluorescence analysis showed that p65, the tran-
scriptionally active subunit of NFkB, was primarily located in the
cytoplasm in untreated cells as expected (Figure 2C, D, first panel).
Following aspirin treatment, there was nuclear accumulation of
p65 in all of the CRC cells (Figure 2C, second panel). However, in
keeping with our observation that there was no IkBa degradation
in the non-CRC cells, aspirin treatment did not induce nuclear
translocation of p65 in any of these cell lines (Figure 2D, second
panel). These data establish that the disparity in viability following
exposure to aspirin in CRC lines compared to lines derived from
other cancer types is associated with markedly differing responses
of the NFkB pathway to aspirin. This work suggests that the effect
of aspirin on NFkB signalling may be implicated in the differential
sensitivity of cancer types to aspirin-induced apoptosis.
Basal IjBa and p65 protein levels and aspirin-induced
apoptosis in CRC cell lines
High basal NFkB activity and aberrant IkBa expression have been
observed in a number of cancers including CRC (Rayet and
Gelinas, 1999). In view of our findings of a cell-type specific NFkB
and death response to aspirin, we considered whether the basal
levels of IkBa and p65 might determine increased sensitivity to
apoptosis, and so could be potential molecular markers of
response. We used immunoblot analysis of cytoplasmic extracts
to examine basal levels of IkBa and p65 in both the CRC and non-
CRC cell lines (Figure 3). There was no difference in expression of
IkBa or p65 or their relative levels (analysed by densitometry, data
not shown) between colorectal and non-CRC cells that could
account for increased sensitivity to apoptosis. These results
indicate that sensitivity to aspirin-induced apoptosis is not related
to the cytoplasmic pool of either protein available for stimulation.
Basal COX-2 protein levels do not determine the NFjB
response to aspirin
Increased COX-2 expression has been observed both in premalig-
nant colonic lesions and CRCs (Eberhart et al, 1994), and COX-2
inhibition has been shown to play a role in aspirin-mediated cell
death (Boolbol et al, 1996). Hence, we considered whether COX-2
expression might explain the heterogeneity of the aspirin response
between the CRC and non-CRC cell lines. Immunoblot analysis of
Aspirin effects on NFjB and apoptosis in cancer cells
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cytoplasmic proteins demonstrated considerable variation in basal
levels of COX-2 between the CRC cell lines (Figure 4). The CRC cell
lines SW480 and HCT116 do not express COX-2, whereas HT-29
and LoVo do express COX-2, and yet all underwent apoptosis
following aspirin treatment. In the non-CRC panel, the MCF-7 cell
line does not express COX-2 but the MDA-MB-231 cell line does
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express COX-2, but neither undergoes aspirin-induced apoptosis.
Similarly, there was variability of COX-2 levels between the CRC
lines and the non-CRC lines (Figure 4). Thus, we found no
association between basal levels of COX-2 expression and
sensitivity to aspirin-induced apoptosis, providing further support
for the notion that COX-independent mechanisms play an
important role in the anti-tumour effect of NSAIDs.
DISCUSSION
The work presented here demonstrates a striking difference in the
response to aspirin between CRC cell lines and lines derived from
other cancer types, with respect to both cell viability and NFkB
signalling. We show that aspirin-induced apoptosis, associated
with IkBa degradation and NFkB nuclear translocation, was
restricted to CRC cells. This relationship between aspirin-induced
apoptosis and the effect on NFkB signalling suggests a molecular
rationale for the particular sensitivity of CRC to NSAIDs compared
to other cancers. These findings also extend our previous
observations on the importance of the NFkB pathway as a key
NSAID target.
Epidemiological evidence indicates that NSAIDs impart greater
protection against CRC than other cancer types, but the molecular
basis for this effect is not known. Several previous reports,
including our own, have shown that aspirin induces apoptosis in
CRC cells (Hanif et al, 1996; Elder et al, 1997; Piazza et al, 1997;
Qiao et al, 1998; Castano et al, 1999; Stark et al, 2001). There is
little data directly comparing the anti-tumour effects of NSAIDs in
vitro between CRC cells and cancer cells of different tissue origin.
A recent study has demonstrated a tissue type-independent effect
in prostate, lung, colon, tongue and pancreatic cancer using nitric
oxide-donating NSAIDs and, although treatment with conven-
tional NSAIDs did have a growth-inhibitory effect, it was observed
at concentrations in excess of the pharmacologically relevant range
after 48 h of treatment (Kashfi et al, 2002). Our findings
demonstrate that aspirin has a considerable degree of specificity
of apoptotic effect for CRC cells compared to other cell lines
studied, and this reflects the epidemiological observations in the
respective tumours. We show that aspirin induces apoptosis in a
panel of CRC cell lines, but has no consistent effect on viability and
apoptosis in cancer cell lines of non-colorectal origin. These results
contrast with some previous reports of NSAID-induced growth
inhibition and apoptosis in breast and endometrial cancer cells
(Noguchi et al, 1995; Planchon et al, 1995; Han et al, 1998; Arango
et al, 2001), but these differences are reconciled by considering
that these studies used NSAIDs other than aspirin (Noguchi et al,
1995; Planchon et al, 1995; Han et al, 1998), while others only
observed apoptosis after long exposures (48– 96 h) to high
concentrations of salicylate out with the therapeutic range
(Sotiriou et al, 1999; Arango et al, 2001). The non-CRC cell lines
are susceptible to other apoptosis-inducing agents and NFkB
activators such as staurosporine and TNFa, respectively, indicating
that these cell lines are not generally resistant to apoptosis or NFkB
modulation (Mooney et al, 2002; Tang et al, 2002). The observation
that aspirin decreased cell viability in one of the three breast
cancer cell lines (T47D) is in keeping with epidemiological data
that suggest a lesser protective effect of NSAIDs against breast
cancer. One cohort epidemiological study showed that the effect of
aspirin use on CRC incidence was reduced in females (Schreine-
machers and Everson, 1994), raising the possibility that differential
protection may be related to gender. However, gender is unlikely
to impart a predominant protective effect, as it has not been borne
out by subsequent studies (Thun et al, 1993). Indeed, the HT-29
CRC cell line is derived from a female patient and is equally
susceptible to aspirin-mediated apoptosis and NFkB modulation
as the other CRC cell lines, which are male in origin. Our findings
clearly indicate important differences between CRC and other
cancer types with respect to aspirin effects on cell viability and
apoptosis.
We show that aspirin-induced apoptosis occurs following IkBa
degradation and NFkB nuclear translocation, and that this effect is
common to all CRC cell lines studied. Notably, this effect on the
NFkB pathway was consistent between CRC cell lines despite
heterogeneity of the lines, with respect to the profile of mutations
in APC, b-catenin, p53 and DNA MMR genes (see Table 1). In
contrast, aspirin treatment did not induce IkBa degradation or
NFkB nuclear translocation in any cell lines derived from cancers
of other tissue types, paralleling the lack of consistent changes in
cell viability and apoptosis in these lines. We have previously
established that the observed effect of aspirin on IkBa and p65 is a
cause of rather than a consequence of apoptosis, based on the
findings that the IkBa degradation was signal-specific and that
nuclear translocation of NFkB and apoptosis were blocked by a
dominant-negative super repressor IkBa (Stark et al, 2001).
Furthermore, we showed that IkB degradation and NFkB nuclear
translocation occur at 2–5 h after aspirin treatment and persists
thereafter to 24 h, whereas apoptosis is not observed to increase
until at least 16 h and continues to 24 h. Hence, the weight of
evidence presented here correlating IkBa degradation and p65
nuclear translocation with apoptosis compared to the lack of
response in non-CRC cell lines provides considerable further
support for a causal role of the NFkB response as an important
component of aspirin-induced apoptosis.
Having shown a striking difference between the CRC and non-
CRC cell lines, with respect to aspirin effects on NFkB signalling
and apoptosis, we investigated potential factors that might
contribute to the ability of specific cell types to undergo apoptosis.
Increased NFkB activity has been observed in CRC (Hardwick et al,
2001) and relative resistance to apoptosis has been attributed to
high constitutive NFkB activity in other cancers (Bours et al, 1994;
Lind et al, 2001; Charalambous et al, 2003). However, we found no
evidence that the specificity of the aspirin-NFkB response is
related to differential expression of basal IkBa or p65 proteins or
their relative expression. The SW480 and HT-29 CRC cell lines
undergo NFkB-mediated apoptosis, despite the considerable
Figure 1 Differential effect of aspirin on cell viability and apoptosis in CRC and non-CRC cell lines. Aspirin treatment (0–10 mM) for 24 h induces a
concentration-dependent decrease in viable cell number (determined by haemocytometric counts) in all CRC cell lines, but there is no consistent change in
the non-colorectal cancer cell lines (A). Annexin V binding assay is used to determine whether all CRC cell lines undergo apoptosis after aspirin treatment
(0–5 mM) for 24 h, but there was no change in apoptosis in the non-CRC cell lines (B). Annexin V binding assay is used to determine whether the non-CRC
cell lines are less susceptible to aspirin-induced apoptosis compared to the CRC cell line SW480 following treatment for 72 h with aspirin (0–3 mM) (C).
The graphs represent three independent experiments and the bars on the graphs are standard error bars.
Table 2 IC50 values for colorectal cancer cell lines
Cell line IC50
HRT-18 3.1270.69
SW480 1.4870.12
HT-29 1.9870.68
DLD-1 2.9270.58
LoVo 2.0770.25
HCT-116 2.7170.46
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Figure 2 Aspirin-induced IkBa degradation and p65 nuclear translocation is restricted to CRC lines. Western blot analysis shows that aspirin treatment
(0–10 mM) for 24 h induces IkBa degradation in a concentration-dependent manner in the CRC cell lines (A), but not in the non-CRC cell lines (B).
Following aspirin treatment, cytoplasmic extracts were made from untreated and treated cells and probed with sheep polyclonal IkBa antibody. The western
blot shown is representative of at least three independent experiments, and Cu/Zn SOD was used as a control for protein loading. Micrographs ( 63) of
immunocytochemically stained cells show that aspirin treatment (10 mM) for 24 h induces nuclear accumulation of p65 in the CRC cell lines (C), but not in
the non-CRC cell lines (D).
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difference in basal NFkB activity previously reported between
these cell lines (Dejardin et al, 1999).
There is substantial rationale for investigating COX-2 as a
potential molecular determinant of response, in view of its role in
CRC development and as a pharmacological target for NSAIDs.
Additionally, it has been reported that the inconclusive nature of
epidemiological data in breast cancer might be related to the
observation that only a subset of breast cancers express COX-2
(Howe et al, 2001). In the work presented here, we did not detect a
relationship between COX-2 protein levels and apoptotic response
to aspirin in any cell type. Furthermore, the fact that we observed
considerable variation in COX-2 expression within the CRC cell
lines, which were all susceptible to aspirin-induced apoptosis,
presents persuasive evidence that COX-2-independent as well as
COX-2-dependent mechanisms play a role in the anti-tumour
effects of NSAIDs (Rigas and Shiff, 2000).
Aspirin concentrations used here are relevant to pharmacolo-
gical levels in clinical practice (1–3 mM) (Insel, 1996). Nonetheless,
comparisons between cell culture concentrations and plasma levels
are somewhat artificial, because of the inability to accurately
mimic in vivo metabolism and tissue concentration of the agent in
epithelial or tumour cells. Decreased basal levels of apoptosis and
hyperproliferative mucosa have been observed in patients with
adenomas, suggesting the existence of a ‘field defect’ in the colonic
mucosa (Anti et al, 2001). Although we observed proportionally
less apoptosis at lower concentrations of aspirin, there is evidence
that low levels of apoptosis translate into significant tumour
regression over time in cell kinetics studies (Pritchard and
Watson, 1996). It remains to be determined whether aspirin
redresses the balance by inducing apoptosis de novo in newly
transformed colorectal epithelial cells destined to become
malignant clones. There is evidence of NFkB involvement in
colonic crypt differentiation and cell turnover in mouse colon,
where NFkB activity is greater in proliferating cells at the base of
crypts compared to mature cells at the surface (Inan et al, 2000).
Thus, it is also possible that the drug corrects deranged
mechanisms that permit escape from normal cellular turnover
and apoptosis.
In summary, the data presented here demonstrate that there are
substantial differences in the anti-tumour effects of aspirin and
modulation of NFkB signalling between cancer cells of different
tissue origin. The effect of aspirin on NFkB signalling and
apoptosis does not appear to be related to expression levels of
COX-2 or mutation status of APC, b-catenin, p53 and DNA MMR
genes. This is important when considering translating these
findings to clinical studies aimed at defining the NFkB response
to aspirin in human colonic epithelium and tumours. The
molecular basis of NSAID anti-tumour activity is complex,
and our findings provide further evidence that the effects of
aspirin on NFkB signalling have particular relevance to CRC
chemoprevention.
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